Regeneron Pharmaceuticals (REGN) Stock Price, Quote, News & History

Q: What sector and industry does Regeneron Pharmaceuticals (REGN) operate in?

Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

Comments

Regeneron Pharmaceuticals Inc (REGN) Stock Price, Quote, News & History

REGNNASDAQ

Logo brought to you by Benzinga Data

Trade with Public

$785.51

18.882.46%

At close: Feb 6, 4:00 PM EST

$783.17

-2.34-0.30%

After Hours: Feb 6, 7:36 PM EST

The dividend Ex-Date is in 12 days

Overview

News Earnings Options Dividends Analyst Ratings Insider Trades Short Interest Government Trades Stock Report

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$769.63

Close

$785.51

Volume / Avg.

671.66K / 963.24K

Day Range

$764.78 - $786.99

52 Wk Range

476.49 - 821.11

Market Cap

$82.31B

P/E Ratio

18.48

Dividend Yield

0.49%

Exchange

NASDAQ

RSI

59

Short Interest

2.3%

Days to Cover

2.56

Recent Regeneron Pharmaceuticals Inc News

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Avi Kapoor

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 margins, higher R&D spending, and a $2 billion U.S. factory plan.

Vandana Singh

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

4.98B

Investing Cash Flow (TTM)

-629.10M

Financing Cash Flow (TTM)

-3.72B

Free Cash Flow (TTM)

3.77B

Capital Expenditure (TTM)

-1.21B

Net Change in Cash (TTM)

634.40M

Analyst Trends and Forecast

2

Nov 25

2

3

Dec 25

3

Jan

4

2

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.3

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$77.14B

PE Ratio (TTM)

18.48

PE Ratio (FWD)

17.42

PEG Ratio (TTM)

1.46

PS Ratio (TTM)

5.80

PB Ratio (TTM)

2.59

Earnings Yield % (TTM)

5.41%

Earnings Yield % (FWD)

5.74%

EV / EBITDA (TTM)

12.92

Price / EBITDA (TTM)

14.31

Price / Free Cash Flow (TTM)

22.11

Book Value / Share

$295.66

Company Debt

Total Debt

$1.99B

LT Debt

$1.99B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$3.12B

Debt to Equity

0.09

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$769.63

Close

$785.51

Volume / Avg.

671.66K / 963.24K

Day Range

$764.78 - $786.99

52 Wk Range

476.49 - 821.11

Market Cap

$82.31B

P/E Ratio

18.48

Dividend Yield

0.49%

Exchange

NASDAQ

RSI

59

Short Interest

2.3%

Days to Cover

2.56

About

Sector

Health Care

Industry

Biotechnology

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry

FAQ

Q

How do I buy Regeneron Pharmaceuticals (REGN) stock?

A

You can purchase shares of Regeneron Pharmaceuticals (NASDAQ:REGN) through any online brokerage.

View our list of the best stock brokerages

Q

Who are Regeneron Pharmaceuticals (REGN) competitors?

A

Other companies in Regeneron Pharmaceuticals’s space includes: Avidity Biosciences Inc (NASDAQ:RNA), BeOne Medicines Ltd (NASDAQ:ONC), Exact Sciences Corp (NASDAQ:EXAS), Neurocrine Biosciences Inc (NASDAQ:NBIX) and Ionis Pharmaceuticals Inc (NASDAQ:IONS).

Q

What is the forecast, or price target, for Regeneron Pharmaceuticals (REGN) stock?

A

Regeneron Pharmaceuticals has a consensus price target of $842.00.

Q

What is the current price for Regeneron Pharmaceuticals (REGN)?

A

The stock price for Regeneron Pharmaceuticals (NASDAQ: REGN) is $783.1749 last updated February 6, 2026 at 7:36 PM EST.

Q

Does Regeneron Pharmaceuticals (REGN) pay a dividend?

A

There are no upcoming dividends for Regeneron Pharmaceuticals.

Q

When is Regeneron Pharmaceuticals (NASDAQ:REGN) reporting earnings?

A

Regeneron Pharmaceuticals does not have any upcoming earnings scheduled.

Q

Is Regeneron Pharmaceuticals (REGN) going to split?

A

There is no upcoming split for Regeneron Pharmaceuticals.

Q

What sector and industry does Regeneron Pharmaceuticals (REGN) operate in?

A

Regeneron Pharmaceuticals is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.

People Also Watch

Avidity Biosciences Inc

Neurocrine Biosciences Inc

NASDAQ:NBIX

$140.36

-0.60%

Ionis Pharmaceuticals Inc

United Therapeutics Corp

NASDAQ:UTHR

$485.36

%

Edge Rankings

Stock Score Locked: Want to See it?

Benzinga Rankings give you vital metrics on any stock – anytime.

Reveal Full Score

Key Statistics

Open

$769.63

Close

$785.51

Volume / Avg.

671.66K / 963.24K

Day Range

$764.78 - $786.99

52 Wk Range

476.49 - 821.11

Market Cap

$82.31B

P/E Ratio

18.48

Dividend Yield

0.49%

Exchange

NASDAQ

RSI

59

Short Interest

2.3%

Days to Cover

2.56

Recent Regeneron Pharmaceuticals Inc News

These Analysts Revise Their Forecasts On Regeneron Pharmaceuticals After Q4 Results

Avi Kapoor

Regeneron Posts Lower Eylea Sales Amid Rising Competition, Plans $2 Billion New Factory

Regeneron beat Q4 earnings and sales estimates as Dupixent gains offset weaker Eylea sales. The drugmaker also outlined 2026 margins, higher R&D spending, and a $2 billion U.S. factory plan.

Vandana Singh

Regeneron Pharmaceuticals Likely To Report Lower Q4 Earnings; These Most Accurate Analysts Revise Forecasts Ahead Of Earnings Call

Avi Kapoor

Financials

Quarterly

Annual

Name

Revenue Change
Gross Change
EBITDA Change
EBIT Change
Earnings Change

Cash Flows

Operating Cash Flow (TTM)

4.98B

Investing Cash Flow (TTM)

-629.10M

Financing Cash Flow (TTM)

-3.72B

Free Cash Flow (TTM)

3.77B

Capital Expenditure (TTM)

-1.21B

Net Change in Cash (TTM)

634.40M

Analyst Trends and Forecast

2

Nov 25

2

3

Dec 25

3

Jan

4

2

Feb

Buy

Hold

Sell

Strong Sell

Analyst Rating and Forecast

3.3

Hold

Strong Buy

Buy

Hold

Sell

Strong Sell

Valuation Metrics

Enterprise Value

$77.14B

PE Ratio (TTM)

18.48

PE Ratio (FWD)

17.42

PEG Ratio (TTM)

1.46

PS Ratio (TTM)

5.80

PB Ratio (TTM)

2.59

Earnings Yield % (TTM)

5.41%

Earnings Yield % (FWD)

5.74%

EV / EBITDA (TTM)

12.92

Price / EBITDA (TTM)

14.31

Price / Free Cash Flow (TTM)

22.11

Book Value / Share

$295.66

Company Debt

Total Debt

$1.99B

LT Debt

$1.99B

LT Debt Issuance (TTM)

-

LT Debt Repayment (TTM)

-

Total Cash

$3.12B

Debt to Equity

0.09

Issuance of Debt (TTM)

-

Repayment of Debt (TTM)

-

Key Statistics

Open

$769.63

Close

$785.51

Volume / Avg.

671.66K / 963.24K

Day Range

$764.78 - $786.99

52 Wk Range

476.49 - 821.11

Market Cap

$82.31B

P/E Ratio

18.48

Dividend Yield

0.49%

Exchange

NASDAQ

RSI

59

Short Interest

2.3%

Days to Cover

2.56

About

Sector

Health Care

Industry

Biotechnology

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet ag...

Compare

EPS better than industry

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

Earnings Per Share

EPS is the portion of a company's profit allocated to each outstanding share of common stock. It is a key metric for investors to assess a company's profitability.

EPS better than industry